Identification and Structure-Activity Studies of 1,3-Dibenzyl-2-aryl imidazolidines as Novel Hsp90 Inhibitors
作者:Yajun Liu、Xiaoxia Liu、Lihong Li、Rui Dai、Meiyun Shi、Hongyu Xue、Yong Liu、Hecheng Wang
DOI:10.3390/molecules24112105
日期:——
promising drug target for cancer therapy. In this work, a virtual screening strategy was employed, leading to the identification of a series of compounds bearing a scaffold of 1,3-dibenzyl-2-aryl imidazolidine as novel Hsp90 inhibitors. Compound 4a showed the highest binding affinity to Hsp90α (IC50 = 12 nM) in fluorescence polarization (FP) competition assay and the strongest anti-proliferative activity
Hsp90(热休克蛋白90)参与了癌症发生和发展的各种过程,因此是一种有前景的癌症治疗药物靶点。在这项工作中,采用了虚拟筛选策略,从而鉴定了一系列带有 1,3-二苄基-2-芳基咪唑烷支架的化合物作为新型 Hsp90 抑制剂。化合物4a在荧光偏振(FP)竞争试验中对Hsp90α的结合亲和力最高(IC50 = 12 nM),对人乳腺癌细胞系(MCF-7)和人肺上皮细胞系(A549)的抗增殖活性最强IC50 值分别为 21.58 μM 和 31.22 μM。蛋白质印迹分析显示,这些新型 Hsp90 抑制剂显着下调了 Hsp90 的客户蛋白 Her2 的表达水平,导致这些新型 Hsp90 抑制剂的细胞毒性。分子对接研究表明,这些新型 Hsp90 抑制剂与 Hsp90 N 末端的三磷酸腺苷 (ATP) 结合位点结合。此外,构效关系研究表明,N-苄基对 1,3-二苄基-2-芳基咪唑烷的抗癌活性很重要。